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ALEFACEPT TREATMENT FOR CHRONIC EXTENSIVE GRAFT VERSUS
HOST DISEASE
Shapira, M.Y., Resnick, I.B., Bitan, M., Tsirigotis, P., Aker, M.,
Gesundeheidt, B., Slavin, S., Or, R. Hadassah – Hebrew University Med-
ical Center, Jerusalem, Israel.
Alefacept (Amevive) is an immunosuppressive dimeric fusion
protein that is used for psoriasis control. We have recently shown
its effect in acute, steroid resistant/dependentGVHD. In this study,
we describe the effect of alefacept treatment on chronic extensive
graft versus host disease (cGVHD). A total of 12 patients (13
cGVHD episodes) were included in this study, alefacept dose for
children and adults was 15 mg and 30 mg once weekly. A median
of 9 (range 1–25) injections were given per patient. Eight out of
12 patients (9/13 episodes) showed response. The median time to
initial response was 2.25 weeks (range 1–8). The response was either
marked (n5 3), moderate (n5 2) or minimal (n5 4). In 2 respond-
ing patients, the response was only temporary. Responding organs
included: skin, oral mucosa, eyes and lungs. Complications that ap-
peared during treatment included infection, pericarditis and squa-
mous cell carcinoma of the lip. All these events may be related to
other drugs given simultaneously. Seven of the twelve patients are
alive all with stable or improved cGVHD. Five patients died due
to GVHD progression while none of the patients experienced re-
lapse of the basic disease. As previously reported in psoriatic pa-
tients treated with alefacept, we found a consistent increase in the
percentage of naive T cells as a consequence of treatment. In con-
clusion, alefacept is effective for the treatment of cGVHD, dose
and treatment’s time intervals should be further explored.381
SILDENAFIL (REVATIO) THERAPY IN CHRONIC GRAFT VERSUS HOST
DISEASE (cGVHD): IMPROVEMENT IN PULMONARY cGVHD SYMPTOMS
Bauer, S.S., Dao, C., Cashen, A., Vij, R., Stockerl-Goldstein, K.,
Uy, G.L., Westervelt, P., DiPersio, J.F., Abboud, C.N. Washington Uni-
versity, St. Louis, MO.
Sildenafil (Revatio) has been used in patients with primary pul-
monary hypertension but its impact on the post allogeneic trans-
plant recipents with chronic lung graft versus host disease
(cGVHD) has not been well characterized. We have noted signifi-
cant improvement in an index case with peripheral acrocyanosis
and dyspnea. Since then we have treated 3 more patients with Reva-
tio as detailed in this report.
Patient 1: 55 yr with Aplastic Anemia 2 years s/p allogeneic pe-
ripheral blood stem cell transplant (PBSC) using single dose TBI
550 cGY/Cy 60 mg/kg. Treatment began on 05/15/06 owing to
acrocyanosis of fingertips and shortness of breath. She improved
dramatically with resolution of cyanotic fingertips and amelioration
of her dyspnea within 6 month of therapy. Patient 2: : 55 yr with
AML, 5 years s/p allogeneic PBSC transplant with single dose
TBI 550 cGY/Cy 60mg/kg 2. She had aGVHDof skin in the first
100 days and developed symptoms of shortness of breath and cough
two years post transplant. Revatio 20 mg tid was begun on 11/2006
with marked improvement of her dyspnea. Patient 3: : 54 yr with
CML 20 months s/p allogeneic marrow stem cell transplant using
fractioned TBI 1200 cGY/Cy 60 mg/kg  2. She had mild GI
aGVHD and developed cough and shortness of breath 1 year post
transplant. Revatio 20 mg tid was started in January of 2007 with
improvement of shortness of breath. Patient 4: 44 yr, 6.5 years s/
p allogeneic PBSC transplant for CML, using single dose TBI
550 cGY/Cy 60 mg/kg  2. He had stage III aGVHD of the skin
and later cGVHD of lungs with cough and dyspnea late in 2006
and noted improvement in pulmonary symptoms. No flushing, di-
arrhea or visual changes were seen in these 4 patients and the
drug has been continued without dose reduction or interruption
in all patients at 20 mg TID. No overt changes in pulmonary
and/or cardiac function were demontrated in this cohort of patients,
indicating that Sildenafil actions may involve mild peripheral arte-
rial and venous vasodilatation in vivo and inhibition of platelets ag-
gregation leading to improved symtomatology. Further clinical
trials carefully monitoring quality of life instruments as well as car-diovascular and pulmonary reserve before and after treatment are
needed to determine the role of Sildenafil in patients with cGVHD.
Individual cardiac and pulmonary function tests are shown below:Cardiopulmonary Studies before and after Sildenafil
ECHO- ECHO-
Patient
#
PFT:
Pre-Revatio
PFT:
Post-Revatio
Pre-
Revatio
Post-
Revatio1 2.78 L 2.23 L Normal NA
2 2.52 L 1.16 L 73% NA
3 2.24 L 2.49 L 62% 60%
4 1.66 L 1.55 L Normal NAPulmonary artery pressure was 27,\30 and 50mmHg in patients 1,
2, 3.382
b2 INTERGRINS SEPARATES GRAFT-VERSUS-HOST DISEASE AND
GRAFT-VERSUS-LEUKEMIA EFFECT
Yu, X.-Z.1, Liang, Y.1, Liu, C.2, Djeu, J.Y.1, Zhong, B.1, Peters, T.3,
Scharffetter-Kochanek, K.3, Anasetti, C.1. 1 H. Lee Moffitt Cancer Center
& Research Institute, Tampa, FL; 2 University of Florida; 3 University of
Ulm, Germany.
Graft-versus-host disease (GVHD) remains a major cause of
morbidity and mortality in allogeneic hematopoietic stem cell
transplantation. Migration of donor-derived T cells into GVHD
target organs plays an essential role in the development of
GVHD. b2 integrins are critically important for leukocyte extrava-
sation through vascular endothelia and for T cell activation. We
asked whether CD18-deficient T cells would induce less GVHD
while sparing graft-versus-leukemia (GVL) effect. Inmurine alloge-
neic bone marrow transplantation models, we found that recipients
of CD18-/- donor T cells had significantly less GVHD morbidity
and mortality compared with recipients ofWT donor T cells. Anal-
ysis of allo-reactivity showed that CD18-/- and WT T cells had
comparable activation, expansion and cytokine production in vivo.
Reduced GVHD was associated with a significant decrease in do-
nor-T cell infiltration of recipient intestine and with an overall de-
crease in pathologic scores in intestine and liver. Finally, we found
that in vivo GVL effect of CD18-/- donor T cells was largely pre-
served, because mortality of the recipients transplanted with
CD18-/- T cells plus tumor cells was greatly delayed or prevented.
Our data suggest that strategies to target b2 intergrin have clinical
potential to alleviate or preventGVHDwhile sparingGVL activity.383
ELUCIDATING THE ROLE OF THE Fas-Fasl PATHWAY DURING CUTANE-
OUS GVHD ACROSS MINOR HISTOCOMPATIBILITY ANTIGENS IN VITRO
Arditti, F.D., Friedman, T., Korngold, R. Hackensack University Med-
ical Center, Hackensack, NJ.
The role of the Fas-FasL pathway in the pathological develop-
ment of graft-vs-host disease (GVHD) directed to miHA remains
unclear. We have recently established a new in vitro culture system
to study cutaneous GVHD in mice and used this system to test the
involvement of the Fas-FasL pathway. Primary epithelial cells
(pEC), constitutively expressing Fas, were obtained from ear skin
of BALB. B mice. Confluent pEC were co-cultured with unsepa-
rated T cells from MHC-matched, miHA-mismatched C57Bl/6
(B6) mice. Two days later, Fas expression was increased on the
pEC (58.76 8.8, as compared to 21.96 3.2 in pEC cultured alone,
p\0.03). To test whether pEC death observed by day 4 in co-cul-
tures was attributed at least in part to the up-regulated Fas, BALB. B
pEC were co-cultured with T cells derived from B6 gld -/gld - mice
(gld). Despite their FasL deficiency, gld T cells killed BALB. B pEC
